Vincenzo Montinaro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9104747/publications.pdf

Version: 2024-02-01

44 papers 1,558 citations

279701 23 h-index 302012 39 g-index

44 all docs

44 docs citations

44 times ranked 2097 citing authors

#	Article	IF	CITATIONS
1	ACE inhibitor-mediated angioedema. International Immunopharmacology, 2020, 78, 106081.	1.7	55
2	Impaired control of the contact system in hereditary angioedema with normal C1â€inhibitor. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1394-1403.	2.7	23
3	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN), Infection, 2019, 47, 141-168.	2.3	0
4	Citation classics: ranking of the top 100 most cited articles in nephrology. CKJ: Clinical Kidney Journal, 2019, 12, 6-18.	1.4	19
5	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN), Internal and Emergency Medicine, 2018, 13, 1139-1166.	1.0	2
6	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). Journal of Nephrology, 2018, 31, 685-712.	0.9	3
7	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). Digestive and Liver Disease. 2018. 50. 1133-1152.	0.4	5
8	Definition of a new cut-off for the anti-phospholipase A2 receptor (PLA2R) autoantibody immunoassay in patients affected by idiopathic membranous nephropathy. Journal of Nephrology, 2018, 31, 899-905.	0.9	25
9	A transcriptomics study of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology, 2018, 142, 883-891.	1.5	18
10	Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study. Clinical and Translational Allergy, 2018, 8, 11.	1.4	3
11	Hereditary Angioedema with Normal C1 Inhibitor: An Italian Case Series. Journal of Allergy and Clinical Immunology, 2017, 139, AB231.	1.5	O
12	The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1214-1222.	1.3	21
13	Longâ€term safety of icatibant treatment of patients with angioedema in realâ€world clinical practice. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 994-998.	2.7	16
14	Complement Modulation of Anti-Aging Factor Klotho in Ischemia/Reperfusion Injury and Delayed Graft Function. American Journal of Transplantation, 2016, 16, 325-333.	2.6	83
15	Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting. Annals of Allergy, Asthma and Immunology, 2016, 117, 394-398.	0.5	78
16	Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. Journal of Antimicrobial Chemotherapy, 2015, 70, 1150-1154.	1.3	42
17	Analysis of characteristics associated with reinjection of icatibant: Results from the Icatibant Outcome Survey. Allergy and Asthma Proceedings, 2015, 36, 399-406.	1.0	19
18	A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy. Orphanet Journal of Rare Diseases, 2015, 10, 11.	1.2	102

#	Article	IF	Citations
19	Endothelial-to-mesenchymal transition and renal fibrosis in ischaemia/reperfusion injury are mediated by complement anaphylatoxins and Akt pathway. Nephrology Dialysis Transplantation, 2014, 29, 799-808.	0.4	98
20	The Problem of Renal Function Monitoring in Patients Treated With the Novel Antiretroviral Drugs. HIV Clinical Trials, 2014, 15, 87-91.	2.0	12
21	Mutational Spectrum of the C1 Inhibitor Gene in a Cohort of Italian Patients with Hereditary Angioedema: Description of Nine Novel Mutations. Annals of Human Genetics, 2014, 78, 73-82.	0.3	34
22	Novel antiretroviral drugs and renal function monitoring of HIV patients. AIDS Reviews, 2014, 16, 144-51.	0.5	31
23	Successful treatment of a facial attack of angioedema with icatibant in a patient with idiopathic angioedema. American Journal of Emergency Medicine, 2013, 31, 1295.e5-1295.e6.	0.7	15
24	De novo homozygous mutation of the C1 inhibitor gene in a patient with hereditary angioedema. Journal of Allergy and Clinical Immunology, 2013, 132, 748-750.e3.	1.5	28
25	Sexual Dysfunction in Women with ESRD Requiring Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 974-981.	2.2	82
26	Early Markers of Tubular Dysfunction in Antiretroviral-Experienced HIV-Infected Patients Treated with Tenofovir Versus Abacavir. AIDS Patient Care and STDs, 2012, 26, 5-11.	1.1	24
27	Prevalence and correlates of erectile dysfunction in men on chronic haemodialysis: a multinational cross-sectional study. Nephrology Dialysis Transplantation, 2012, 27, 2479-2488.	0.4	44
28	Efficacy and safety of recombinant human C1â€inhibitor for the treatment of attacks of hereditary angioedema: European openâ€label extension study. Clinical and Experimental Allergy, 2012, 42, 929-935.	1.4	50
29	Renal complications in HIV disease: between present and future. AIDS Reviews, 2012, 14, 37-53.	0.5	29
30	Acquired Angioedema with C1 Inhibitor Deficiency Associated with Anticardiolipin Antibodies. International Journal of Immunopathology and Pharmacology, 2011, 24, 1115-1118.	1.0	6
31	The Employment of Leukotriene Antagonists in Cutaneous Diseases Belonging to Allergological Field. Mediators of Inflammation, 2010, 2010, 1-6.	1.4	15
32	Therapeutic Targeting of Classical and Lectin Pathways of Complement Protects from Ischemia-Reperfusion-Induced Renal Damage. American Journal of Pathology, 2010, 176, 1648-1659.	1.9	136
33	Immature myeloid and plasmacytoid dendritic cells infiltrate renal tubulointerstitium in patients with lupus nephritis. Molecular Immunology, 2008, 45, 259-265.	1.0	121
34	A randomised, placebo-controlled, double blind phase III study of the efficacy and safety of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema. Molecular Immunology, 2008, 45, 4118-4119.	1.0	1
35	Glomerular clusterin is associated with PKC- $\hat{l}\pm/\hat{l}^2$ regulation and good outcome of membranous glomerulonephritis in humans. Kidney International, 2006, 70, 477-485.	2.6	26
36	CD40 Ligand Increases Complement C3 Secretion by Proximal Tubular Epithelial Cells. Journal of the American Society of Nephrology: JASN, 2005, 16, 2003-2011.	3.0	23

#	Article	IF	CITATION
37	Renal C3 synthesis in idiopathic membranous nephropathy: Correlation to urinary C5b-9 excretion. Kidney International, 2000, 57, 137-146.	2.6	28
38	Cytokine, chemokine and growth factor expression in the pathogenesis of progressive renal damage. Nephrology, 1997, 3, s663-s669.	0.7	2
39	Monocyte recruitment in cryoglobulinemic membranoproliferative glomerulonephritis: A pathogenetic role for monocyte chemotactic peptide-1. Kidney International, 1997, 51, 155-163.	2.6	44
40	Progression of renal damage in human glomerulonephritides: Is there sleight of hand in winning the game?. Kidney International, 1997, 52, 1439-1457.	2.6	82
41	Biosynthesis of C3 by human mesangial cells. Modulation by proinflammatory cytokines. Kidney International, 1995, 47, 829-836.	2.6	32
42	Primary IgA Nephropathy: The Relevance of Experimental Models in the Understanding of Human Disease. Nephron, 1992, 62, 373-381.	0.9	10
43	Extrarenal cytokines modulate the glomerular response to IgA immune complexes. Kidney International, 1992, 42, 341-353.	2.6	65
44	The Role of Polymeric IgA in Complement-Mediated Solubilization of IgG and IgA Immune Complexes. American Journal of Kidney Diseases, 1988, 12, 433-436.	2.1	6